Lung cancer drug trial pulled before it even started
NCT ID NCT04992858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test the safety and effectiveness of ningetinib in people with advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. The trial planned to enroll adults aged 18-75 with stage IIIB-IV cancer. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail targets Hard-to-Treat lung cancer mutation
- Experimental drug targets Hard-to-Treat lung cancer
- Could your own tumor cells beat lung cancer? new trial tests it
- New hope for tough lung cancers: dual-antibody combo targets tumors from two angles
- Lung cancer gene map after drug failure could guide next steps